Biomarkers Market (2011 – 2020)

2012-02-02
Published : Feb-2012

A biomarker is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic response to a therapeutic intervention. Biomarkers are classified in different ways based on different parameters such as on the basis of their application, their characteristics and on their usage in decision making in early drug development. With drug development facing challenges from ever increasing cost of developing drugs and rise in the failure rate for drugs in phase II and III clinical trials, biomarkers are being employed on large scale by pharmaceutical companies to overcome these challenges. Also the advent of personalized medicine and companion diagnostics is witnessing a strong presence of use of biomarkers and holds to be a big opportunity for the overall biomarker market.

Biomarkers Market

The global biomarker market is also growing due to emergence of several new companies, providing advanced technology platforms in areas such as bioinformatics, genomics, metabolomics, transcriptomics, proteomics, and pharmacogenomics. Scientific progress in these areas likely to be a key driver for further biomarker research to improve sample throughputs, enhance detection levels, and generate multiple biomarker panels with increased utility in diagnostics, preclinical research, clinical trials and product commercialization.

This report studies the global biomarker market divided into global discovery technologies market, global application market across major indications which is given as a different segment; Global biomarker indication market over the forecast period (2011-2020). The global biomarker market is valued at $13.16 billion in 2011 growing at a steady pace of CAGR 14.40% to reach $25.79 billion by 2016. The biomarker discovery technology market is the major contributor of this market followed by the application market. Oncology is seen to be the largest indication in terms of revenue but cardiology is the fastest growing indication with a CAGR of 16.24% from 2011 to 2016. North America is leading the market followed by Europe and Asia is the fastest growing region due to high adoption rate of high throughput technologies for biomarker discovery and rapid growth of IT industry in this region.

Players are implementing various growth strategies in the market to gain competitive edge. New products launch, agreements and collaborations, partnerships, joint ventures, mergers and acquisitions, were some of the major strategies adopted by the players during the study period between January 2009 and December 2011. Our research indicates that agreements, partnerships, collaborations, and new joint ventures form a major growth strategy in the Global Biomarker Market accounting for a 42% share in this market.

Scope of the report

This Biomarkers Market research report categorizes on the basis of discovery technologies and application market across major indications; forecasting revenues and analyzing trends in each of the following submarkets:

The report categorizes the global biomarker market as follows:

  • Discovery technologies (Omics technologies comprising genomics, proteomics, metabolomics, transcriptomics and epigenomics; imaging technologies comprising PET, SPECT, CT, MRI, ultrasound, and bioinformatics)
  • Services market (Assay production and development, biomarker testing, and biomarker validation)
  • Applications market (drug development and discovery, personalized medicine, and molecular diagnostics)
  • Indications (Oncology, cardiology, neurology, and others)

On the basis of geography:

  • North America
  • Europe
  • Asia
  • ROW

In addition to market data on the submarkets of the global biomarker market, each section of the report will identify and analyze the market trends, opportunities, and the factors driving or inhibiting market growth. The report will also draw a competitive landscape, in which it will profile 40 key market players.

TABLE OF CONTENTS

1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 STAKEHOLDERS
1.4 RESEARCH METHODOLOGY
1.4.1 MARKET SIZE
1.4.2 KEY DATA POINTS FROM SECONDARY SOURCES
1.4.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW 
3.1 DEFINITION OF BIOMARKERS
3.2 BIOMARKERS & ITS TYPES
3.3 BIOMARKERS MARKET
3.3.1 MARKET SEGMENTATION
3.3.2 CHALLENGES & OPPORTUNITIES
3.3.2.1 Challenges
3.3.2.1.1 Variability
3.3.2.1.2 Ethical considerations & acceptability
3.3.2.2 Opportunities
3.3.2.2.1 Personalized medicine
3.3.2.2.2 Companion diagnostics
3.3.3 DRIVERS & RESTRAINTS
3.3.3.1 Drivers
3.3.3.1.1 High demand boosts the growth of the biomarker market globally
3.3.3.1.2 Strategic collaborations lead to increasing applications in the market
3.3.3.1.3 Technological advances contribute to growth
3.3.3.1.4 The rising prevalence of the disease forms
3.3.3.1.5 FDA support for biomarker development
3.3.3.2 Restraints
3.3.3.2.1 Low capital investment & cost-benefit hinders growth of biomarkers
3.3.3.2.2 Biomarkers not a profitable market for small organizations
3.3.3.2.3 Sample collection & storage
3.3.3.2.4 Limited biomarker validation
3.3.3.2.5 Need for new R&D models with greater precision & flexibility

4 GLOBAL BIOMARKER MARKET, BY DISCOVERY TECHNOLOGIES 
4.1 INTRODUCTION
4.2 IMAGING TECHNOLOGIES FOR BIOMARKER DISCOVERY
4.2.1 POSITRON EMISSION TOMOGRAPHY (PET)
4.2.2 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY(SPECT)
4.2.3 ULTRASOUND
4.2.4 MAGNETIC RESONANCE IMAGING (MRI)
4.2.5 COMPUTED TOMOGRAPHY (CT)
4.3 OMICS TECHNOLOGIES FOR BIOMARKER DISCOVERY
4.3.1 PROTEOMICS
4.3.1.1 Mass spectrometry
4.3.1.1.1 MALDI mass spectrometry
4.3.1.1.2 Imaging mass spectrometry
4.3.1.2 2D Gel Electrophoresis
4.3.1.3 Protein microarray technology
4.3.1.4 Antibody array technology
4.3.1.5 Peptide array technology
4.3.2 GENOMICS
4.3.2.1 Whole genome sequencing
4.3.2.2 Genotyping
4.3.2.3 Epigenetics
4.3.3 TRANSCRIPTOMICS
4.3.3.1 Microarrays
4.3.3.2 Gene expression profiling
4.3.4 METABOLOMICS
4.3.4.1 Capillary electrophoresis
4.3.4.2 Mass spectrometry based kits
4.3.4.3 Nuclear Magnetic Resonance(NMR)
4.4 BIOINFORMATICS
4.4.1 CLUSTER ANALYSIS
4.4.2 STATISTICAL ANALYSIS
4.4.3 CELL SIGNAL PATHWAYS
4.4.4 COMPUTER AIDED DESIGN
4.4.5 DATA MINING
4.4.6 PROTEIN INTERACTION MAPS

5 SERVICES MARKET OF BIOMARKERS 
5.1 INTRODUCTION
5.2 CLINICAL
5.2.1 SAMPLE PREPARATION
5.2.2 ASSAY DEVELOPMENT
5.2.3 BIOMARKER VALIDATION & TESTING
5.2.3.1 Feasibility Studies and choice of assay & biomarker
5.2.3.2 Long lead time required for Biomarker Assay preparation
5.3 BIOINFORMATICS
5.3.1 FUNCTIONAL GENOMICS & PROTEOMICS DRIVE THE DEMAND FOR BIOINFORMATICS

6 BIOMARKER APPLICATION MARKET 
6.1 INTRODUCTION
6.2 DRUG DISCOVERY & DEVELOPMENT
6.2.1 CLINICAL TRIALS
6.2.1.1 Preclinical Development
6.2.1.2 Phase I drug development
6.2.1.3 Phase II drug development
6.2.1.4 Phase III drug development
6.2.1.5 Phase IV drug development
6.3 PERSONALIZED MEDICINE
6.4 MOLECULAR DIAGNOSTICS
6.4.1 MOLECULAR DIAGNOSTICS IS A DYNAMIC & RAPIDLY BROADENING MARKET
6.4.2 TRENDS IN THE DIAGNOSTICS MARKET
6.4.3 CHALLENGES
6.4.3.1 Nucleic acids pose a challenge to the molecular diagnostics field
6.4.3.2 Molecular diagnostics market lacks a collaborated effort
6.4.4 DRIVER
6.4.4.1 Increase in the incidence of diseases spurs the growth of the diagnostics market
6.4.5 RESTRAINT
6.4.5.1 The “interest-information” restricts growth of molecular diagnostics
6.4.6 MOLECULAR DIAGNOSTICS IN MAJOR INDICATIONS
6.4.6.1 Oncology
6.4.6.2 Cardiology
6.4.6.3 Neurology
6.4.6.4 Other treatment areas
6.4.7 BIOMARKERS IN DIAGNOSTICS
6.4.8 BENEFITS OF MOLECULAR DIAGNOSTICS

7 BIOMARKER INDICATION MARKET 
7.1 INTRODUCTION
7.2 ONCOLOGY BIOMARKER MARKET
7.2.1 ONCOLOGY BIOMARKER DISCOVERY MARKET
7.2.1.1 Genomics
7.2.1.2 Proteomics
7.2.1.3 Metabolomics
7.2.1.4 Transcriptomics
7.2.1.5 Other Omics
7.2.1.6 Imaging
7.2.2 DRUG DISCOVERY & DEVELOPMENT
7.2.3 CANCER TYPES
7.2.3.1 Ovarian Cancer
7.2.3.2 Breast Cancer
7.2.3.3 Bladder Cancer
7.2.3.4 Cervical Cancer
7.2.3.5 Prostate Cancer
7.2.3.6 Lung Cancer
7.2.3.7 Colorectal Cancer
7.3 CARDIOLOGY BIOMARKERS MARKET
7.3.1 CARDIOLOGY BIOMARKER DISCOVERY MARKET
7.3.1.1 Genomics
7.3.1.2 Proteomics
7.3.1.3 Metabolomics
7.3.1.4 Transcriptomics
7.3.1.5 Imaging
7.3.1.6 Bioinformatics
7.3.2 DRUG DISCOVERY & DEVELOPMENT
7.3.3 CARDIAC MARKERS, BY DISEASE TYPES
7.3.3.1 Acute Coronary Syndrome
7.3.3.2 Coronary artery disease
7.3.3.3 Stroke
7.3.4 CARDIOLOGY BIOMARKERS USED IN THE MARKET
7.4 NEUROLOGY BIOMARKER MARKET
7.4.1 NEUROLOGY BIOMARKER DISCOVERY MARKET
7.4.1.1 Omics technologies
7.4.1.2 Imaging Technologies
7.4.2 DRUG DISCOVERY & DEVELOPMENT
7.4.3 DISEASE TYPES
7.4.3.1 Alzheimer’s disease
7.4.3.2 Parkinson’s disease
7.4.3.3 Multiple sclerosis
7.4.3.4 Schizophrenia
7.4.3.5 Amyotrophic Lateral Sclerosis
7.4.3.6 Epilepsy
7.5 OTHER INDICATIONS BIOMARKER MARKET
7.5.1 OTHER INDICATION BIOMARKER DISCOVERY MARKET
7.5.1.1 Omics technologies
7.5.1.2 Imaging technologies
7.5.2 DRUG DISCOVERY & DEVELOPMENT
7.6 DISEASE TYPES
7.6.1 HIV
7.6.1.1 Immunological & Virological Markers in HIV Infection
7.7 RENAL FAILURE
7.8 ARTHRITIS
7.9 TUBERCULOSIS
7.10 DIABETES

8 GEOGRAPHICAL ANALYSIS 
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.3 EUROPE
8.4 ASIA
8.5 ROW

9 COMPETITIVE LANDSCAPE 
9.1 KEY STRATEGIES
9.2 MERGERS & ACQUISITIONS
9.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
9.4 NEW PRODUCTS LAUNCH
9.5 OTHER DEVELOPMENTS

10 COMPANY PROFILES 
10.1 ABBOTT LABORATORIES
10.1.1 OVERVIEW
10.1.2 FINANCIALS
10.1.3 PRODUCTS & SERVICES
10.1.4 STRATEGY
10.1.5 DEVELOPMENTS
10.2 ABCODIA LTD
10.2.1 OVERVIEW
10.2.2 FINANCIALS
10.2.3 PRODUCTS & SERVICES
10.2.4 STRATEGY
10.2.5 DEVELOPMENTS
10.3 AFFYMETRIX INC
10.3.1 OVERVIEW
10.3.2 FINANCIALS
10.3.3 PRODUCTS & SERVICES
10.3.4 STRATEGY
10.3.5 DEVELOPMENTS
10.4 AGILENT TECHNOLOGIES INC
10.4.1 OVERVIEW
10.4.2 FINANCIALS
10.4.3 PRODUCTS & SERVICES
10.4.4 STRATEGY
10.4.5 DEVELOPMENTS
10.5 AMGEN INC
10.5.1 OVERVIEW
10.5.2 FINANCIALS
10.5.3 PRODUCTS & SERVICES
10.5.4 STRATEGY
10.5.5 DEVELOPMENT
10.6 ASTRAZENECA PLC
10.6.1 OVERVIEW
10.6.2 FINANCIALS
10.6.3 PRODUCTS & SERVICES
10.6.4 STRATEGY
10.6.5 DEVELOPMENTS
10.7 AUGUREX LIFE SCIENCES CORP
10.7.1 OVERVIEW
10.7.2 FINANCIALS
10.7.3 PRODUCTS & SERVICES
10.7.4 STRATEGY
10.7.5 DEVELOPMENTS
10.8 AUSHON BIOSYSTEMS INC
10.8.1 OVERVIEW
10.8.2 FINANCIALS
10.8.3 PRODUCTS & SERVICES
10.8.4 STRATEGY
10.8.5 DEVELOPMENTS
10.9 BAYER AG
10.9.1 OVERVIEW
10.9.2 FINANCIALS
10.9.3 PRODUCTS & SERVICES
10.9.4 STRATEGY
10.9.5 DEVELOPMENTS
10.1 BECKMAN COULTER INC
10.10.1 OVERVIEW
10.10.2 FINANCIALS
10.10.3 PRODUCTS & SERVICES
10.10.4 STRATEGY
10.10.5 DEVELOPMENTS
10.11 BGI
10.11.1 OVERVIEW
10.11.2 FINANCIALS
10.11.3 PRODUCTS & SERVICES
10.11.4 STRATEGY
10.11.5 DEVELOPMENTS
10.12 BIOCRATES LIFE SCIENCES AG
10.12.1 OVERVIEW
10.12.2 FINANCIALS
10.12.3 PRODUCTS & SERVICES
10.12.4 STRATEGY
10.12.5 DEVELOPMENTS
10.13 BIOMARKER STRATEGIES
10.13.1 OVERVIEW
10.13.2 FINANCIALS
10.13.3 PRODUCTS & SERVICES
10.13.4 STRATEGY
10.13.5 DEVELOPMENTS
10.14 BIOSYSTEMS INTERNATIONAL
10.14.1 OVERVIEW
10.14.2 FINANCIALS
10.14.3 PRODUCTS & SERVICES
10.14.4 STRATEGY
10.14.5 DEVELOPMENTS
10.15 BRISTOL-MYERS SQUIBB
10.15.1 OVERVIEW
10.15.2 FINANCIALS
10.15.3 PRODUCTS & SERVICES
10.15.4 STRATEGY
10.15.5 DEVELOPMENTS
10.16 CRESCENDO BIOSCIENCE
10.16.1 OVERVIEW
10.16.2 FINANCIALS
10.16.3 PRODUCTS & SERVICES
10.16.4 STRATEGY
10.16.5 DEVELOPMENTS
10.17 EISAI CO. LTD.
10.17.1 OVERVIEW
10.17.2 FINANCIALS
10.17.3 PRODUCTS & SERVICES
10.17.4 STRATEGY
10.17.5 DEVELOPMENTS
10.18 EPIONTIS GMBH
10.18.1 OVERVIEW
10.18.2 FINANCIALS
10.18.3 PRODUCTS & SERVICES
10.18.4 DEVELOPMENTS
10.19 EPISTEM HOLDINGS PLC
10.19.1 OVERVIEW
10.19.2 FINANCIALS
10.19.3 PRODUCTS & SERVICES
10.19.4 STRATEGY
10.19.5 DEVELOPMENTS
10.20 EUROGENTEC S.A.
10.20.1 OVERVIEW
10.20.2 FINANCIALS
10.20.3 PRODUCTS & SERVICES
10.20.4 STRATEGY
10.20.5 DEVELOPMENTS
10.21 EVOTEC AG
10.21.1 OVERVIEW
10.21.2 FINANCIALS
10.21.3 PRODUCTS & SERVICES
10.21.4 STRATEGY
10.21.5 DEVELOPMENTS
10.22 GLAXOSMITHKLINE PLC
10.22.1 OVERVIEW
10.22.2 FINANCIALS
10.22.3 PRODUCTS & SERVICES
10.22.4 STRATEGY
10.22.5 DEVELOPMENTS
10.23 IPSEN
10.23.1 OVERVIEW
10.23.2 FINANCIALS
10.23.3 PRODUCTS & SERVICES
10.23.4 STRATEGY
10.23.5 DEVELOPMENTS
10.24 JOHNSON & JOHNSON
10.24.1 OVERVIEW
10.24.2 FINANCIALS
10.24.3 PRODUCTS & SERVICES
10.24.4 STRATEGY
10.24.5 DEVELOPMENTS
10.25 MERCK & CO.
10.25.1 OVERVIEW
10.25.2 FINANCIALS
10.25.3 PRODUCTS & SERVICES
10.25.4 STRATEGY
10.25.5 DEVELOPMENTS
10.26 MICROMEDIC TECHNOLOGIES LTD
10.26.1 OVERVIEW
10.26.2 PRODUCTS & SERVICES
10.26.3 STRATEGY
10.26.4 DEVELOPMENTS
10.27 MYRIAD GENETICS INC
10.27.1 OVERVIEW
10.27.2 FINANCIALS
10.27.3 PRODUCTS & SERVICES
10.27.4 STRATEGY
10.27.5 DEVELOPMENTS
10.28 NEXTGEN SCIENCES INC
10.28.1 OVERVIEW
10.28.2 FINANCIALS
10.28.3 PRODUCTS & SERVICES
10.28.4 STRATEGY
10.28.5 DEVELOPMENTS
10.29 NOVARTIS INTERNATIONAL AG
10.29.1 OVERVIEW
10.29.2 FINANCIALS
10.29.3 PRODUCTS & SERVICES
10.29.4 STRATEGY
10.29.5 DEVELOPMENTS
10.30 OCIMUM BIOSOLUTIONS LTD
10.30.1 OVERVIEW
10.30.2 FINANCIALS
10.30.3 PRODUCTS & SERVICES
10.30.4 STRATEGY
10.30.5 DEVELOPMENTS
10.31 PFIZER INC
10.31.1 OVERVIEW
10.31.2 FINANCIALS
10.31.3 PRODUCTS & SERVICES
10.31.4 STRATEGY
10.31.5 DEVELOPMENTS
10.32 PRONOTA NV
10.32.1 OVERVIEW
10.32.2 FINANCIALS
10.32.3 PRODUCTS & SERVICES
10.32.4 STRATEGY
10.32.5 DEVELOPMENTS
10.33 QUINTILES TRANSNATIONAL CORPORATION
10.33.1 OVERVIEW
10.33.2 FINANCIALS
10.33.3 PRODUCTS & SERVICES
10.33.4 STRATEGY
10.33.5 DEVELOPMENTS
10.34 QIAGEN NV
10.34.1 OVERVIEW
10.34.2 FINANCIALS
10.34.3 PRODUCTS & SERVICES
10.34.4 STRATEGY
10.34.5 DEVELOPMENTS
10.35 ROCHE DIAGNOSTICS LIMITED
10.35.1 OVERVIEW
10.35.2 FINANCIALS
10.35.3 PRODUCTS & SERVICES
10.35.4 STRATEGY
10.35.5 DEVELOPMENT
10.36 SANOFI-AVENTIS
10.36.1 OVERVIEW
10.36.2 FINANCIALS
10.36.3 PRODUCTS & SERVICES
10.36.4 STRATEGY
10.36.5 DEVELOPMENT
10.37 SIEMENS HEALTHCARE
10.37.1 OVERVIEW
10.37.2 FINANCIALS
10.37.3 PRODUCTS & SERVICES
10.37.4 STRATEGY
10.37.5 DEVELOPMENTS
10.38 TRANS-HIT BIOMARKERS INC
10.38.1 OVERVIEW
10.38.2 FINANCIALS
10.38.3 PRODUCTS & SERVICES
10.38.4 STRATEGY
10.38.5 DEVELOPMENTS
10.39 PACIFIC BIOMARKERS INC
10.39.1 OVERVIEW
10.39.2 FINANCIALS
10.39.3 PRODUCTS & SERVICES
10.39.4 STRATEGY
10.39.5 DEVELOPMENTS
10.40 CAPRION PROTEOMICS INC.
10.40.1 OVERVIEW
10.40.2 FINANCIALS
10.40.3 PRODUCTS & SERVICES
10.40.4 STRATEGY
10.40.5 DEVELOPMENTS
10.41 PROTEOME SCIENCES PLC
10.41.1 OVERVIEW
10.41.2 FINANCIALS
10.41.3 PRODUCTS & SERVICES
10.41.4 STRATEGY
10.41.5 DEVELOPMENTS
10.42 VERMILLION INC
10.42.1 OVERVIEW
10.42.2 FINANCIALS
10.42.3 PRODUCTS & SERVICES
10.42.4 STRATEGY
10.42.5 DEVELOPMENTS

LIST OF TABLES  

TABLE 1 GLOBAL BIOMARKER MARKET REVENUE, BY SEGMENTS, 2009 – 2020 ($MILLION)
TABLE 2 GLOBAL BIOMARKER MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 3 GLOBAL BIOMARKER DISCOVERY MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 4 BIOMARKER DISCOVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 5 GLOBAL BIOMARKER DISCOVERY MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 6 BIOMARKER IMAGING TECHNOLOGIES MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 7 GLOBAL BIOMARKER DISCOVERY MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 8 GLOBAL BIOMARKER OMICS TECHNOLOGIES MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 9  BIOMARKER OMICS TECHNOLOGIES MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 10 GLOBAL PROTEOMICS BIOMARKER MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 11 GLOBAL GENOMICS BIOMARKER MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 12 GLOBAL TRANSCRIPTOMICS BIOMARKER MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 13 GLOBAL METABOLOMICS BIOMARKER MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 14 GLOBAL BIOMARKER BIOINFORMATICS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 15 BIOMARKER BIOINFORMATICS MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 16 GLOBAL BIOMARKER MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION)
TABLE 17 GLOBAL BIOMARKER APPLICATION MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 18 BIOMARKER APPLICATION MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 19 GLOBAL BIOMARKER DRUG DISCOVERY & DEVELOPMENT PROCESS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 20 BIOMARKER DRUG DISCOVERY & DEVELOPMENT PROCESS MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 21 GLOBAL BIOMARKER APPLICATION MARKET, BY PHASES IN DRUG DISCOVERY & DEVELOPMENT PROCESS, 2009 – 2020 ($MILLION)
TABLE 22 GLOBAL BIOMARKER PRECLINICAL STUDY MARKET, BY VARIOUS INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 23 GLOBAL BIOMARKER PHASE I MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 24 GLOBAL BIOMARKER PHASE II MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 25 GLOBAL BIOMARKER PHASE III MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 26 GLOBAL BIOMARKER PHASE IV MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 27 PERSONALIZED MEDICINE(PM) USING BIOMARKERS IN CURRENT DRUG LABELS
TABLE 28 GLOBAL BIOMARKER PERSONALIZED MEDICINE MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 29 BIOMARKER PERSONALIZED MEDICINE MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 30 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 31 MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 32 GLOBAL BIOMARKER MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 33 GLOBAL ONCOLOGY BIOMARKER MARKET, BY SEGMENTS, 2009 – 2020 ($MILLION)
TABLE 34 GLOBAL ONCOLOGY BIOMARKER MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 35 GLOBAL ONCOLOGY BIOMARKER MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 36 GLOBAL ONCOLOGY BIOMARKER MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 37 GLOBAL ONCOLOGY BIOMARKER MARKET, BY PHASES, 2009 – 2020 ($MILLION)
TABLE 38 GLOBAL ONCOLOGY BIOMARKER MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION)
TABLE 39 ONCOLOGY BIOMARKER MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 40 GLOBAL CARDIOLOGY BIOMARKERS MARKET REVENUE, BY SEGMENTS, 2009 – 2020 ($MILLION)
TABLE 41 GLOBAL CARDIOLOGY BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 42 GLOBAL CARDIOLOGY BIOMARKER MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 43 GLOBAL CARDIOLOGY BIOMARKER MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 44 GLOBAL CARDIOLOGY BIOMARKER MARKET, BY PHASES, 2009 – 2020 ($MILLION)
TABLE 45 GLOBAL CARDIOLOGY MARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 46 COMMONLY USED CARDIAC BIOMARKER TESTS
TABLE 47 BIOMARKER TESTS USED FOR PROGNOSIS
TABLE 48 CARDIAC MARKERS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 49 GLOBAL NEUROLOGY BIOMARKER MARKET, BY SEGMENTS, 2009 – 2020 ($MILLION)
TABLE 50 GLOBAL NEUROLOGY BIOMARKER MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 51 GLOBAL NEUROLOGY BIOMARKER MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 52 GLOBAL NEUROLOGY BIOMARKER MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 53 GLOBAL NEUROLOGY BIOMARKER MARKET, BY PHASES, 2009 – 2020 ($MILLION)
TABLE 54 GLOBAL NEUROLOGY BIOMARKER MARKET, BY DISEASE TYPES, 2009– 2020 ($MILLION)
TABLE 55 NEUROLOGY BIOMARKER MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 56 GLOBAL OTHER INDICATIONS BIOMARKER MARKET, BY SEGMENTS, 2009 – 2020 ($MILLION)
TABLE 57 GLOBAL OTHER INDICATIONS BIOMARKER MARKET REVENUE, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 58 GLOBAL OTHER INDICATION BIOMARKER MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 59 GLOBAL OTHER INDICATION BIOMARKER MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 60 GLOBAL OTHER INDICATION BIOMARKER MARKET, BY PHASES, 2009 – 2020 ($MILLION)
TABLE 61 GLOBAL OTHER INDICATIONS BIOMARKER MARKET, BY TYPES, 2009 – 2020 ($MILLION)
TABLE 62 HIV BIOMARKERS
TABLE 63 RENAL BIOMARKERS
TABLE 64 OTHER INDICATIONS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 65 BIOMARKERS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2020 ($BILLION)
TABLE 66 NORTH AMERICA: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 67 NORTH AMERICA: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 68 NORTH AMERICA: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 69 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION)
TABLE 70 NORTH AMERICA: BIOMARKERS MARKET, BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION)
TABLE 71 NORTH AMERICA: BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 72 NORTH AMERICA: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION)
TABLE 73 NORTH AMERICA: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 74 NORTH AMERICA: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 75 NORTH AMERICA: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION)
TABLE 76 EUROPE: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 77 EUROPE: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 78 EUROPE: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 79 EUROPE: BIOMARKERS MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION)
TABLE 80 EUROPE: BIOMARKERS MARKET, BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION)
TABLE 81 EUROPE: BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 82 EUROPE: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION)
TABLE 83 EUROPE: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 84 EUROPE: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 85 EUROPE: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION)
TABLE 86 ASIA: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 87 ASIA: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 88 ASIA: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 89 ASIA: BIOMARKERS MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION)
TABLE 90 ASIA: BIOMARKERS MARKET, BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION)
TABLE 91 ASIA: BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 92 ASIA: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION)
TABLE 93 ASIA: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 94 ASIA: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 95 ASIA: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION)
TABLE 96 ROW: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 97 ROW: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 98 ROW: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 99 ROW: BIOMARKERS MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION)
TABLE 100 ROW: BIOMARKERS MARKET, BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION)
TABLE 101 ROW: BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 102 ROW: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION)
TABLE 103 ROW: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 104 ROW: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 105 ROW: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION)
TABLE 106 MERGERS & ACQUISITIONS (JANUARY 2009 – DECEMBER 2011)
TABLE 107 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (JANUARY 2009 – DECEMBER 2011)
TABLE 108 NEW PRODUCTS LAUNCH (JANUARY 2009 – DECEMBER 2011)
TABLE 109 OTHER DEVELOPMENTS (JANUARY 2009 – DECEMBER 2011)
TABLE 110 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 111 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 112 ABBOTT LABORATORIES: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 113 AFFYMETRIX INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 114 AFFYMETRIX INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 115 AFFYMETRIX INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 116 AGILENT TECHNOLOGIES INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 117 AGILENT TECHNOLOGIES INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 118 AGILENT TECHNOLOGIES INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 119 AMGEN INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 120 AMGEN INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 121 ASTRAZENECA PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 122 ASTRAZENECA PLC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 123 ASTRAZENECA PLC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 124 BAYER AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 125 BAYER AG: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 126 BAYER AG: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 127 BECKMAN COULTER INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 128 BECKMAN COULTER INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 129 BECKMAN COULTER INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 130 BRISTOL-MYERS SQUIBB: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 131 BRISTOL-MYERS SQUIBB: TOTAL REVENUES, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 132 BRISTOL-MYERS SQUIBB: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 133 EISAI CO. LTD: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 134 EISAI CO. LTD: TOTAL REVENUES, BY SEGMENTS, 2009 – 2011 ($MILLION)
TABLE 135 EISAI CO. LTD: REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 136 EPISTEM HOLDINGS PLC: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 137 EPISTEM HOLDINGS PLC: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)
TABLE 138 EPISTEM HOLDINGS PLC: REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 139 EVOTEC AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 140 EVOTEC AG: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 141 GLAXOSMITHKLINE PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2011 ($MILLION)
TABLE 142 GLAXOSMITHKLINE PLC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2011 ($MILLION)
TABLE 143 GLAXOSMITHKLINE PLC: REVENUE FOR PHARMACEUTICAL SEGMENT, BY GEOGRAPHY, 2008 – 2011 ($MILLION)
TABLE 144 IPSEN: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 145 IPSEN: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 146 IPSEN: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 147 JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 148 JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENTS, 2008 -2010 ($MILLION)
TABLE 149 MEDICAL DEVICES & DIAGNOSTICS SEGMENT REVENUE, 2008 – 2010 ($MILLION)
TABLE 150 JOHNSON & JOHNSON: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 151 MERCK & CO: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 152 MERCK & CO: TOTAL REVENUES, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 153 MERCK & CO: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 154 MYRIAD GENETICS INC: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 155 MYRIAD GENETICS INC: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)
TABLE 156 NEXTGEN GROUP PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 157 NEXTGEN GROUP PLC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 158 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 159 NOVARTIS INTERNATIONAL AG: TOTAL REVENUES, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 160 NOVARTIS INTERNATIONAL AG: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 161 PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 162 PFIZER INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 163 PFIZER INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 164 QIAGEN N.V: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 165 QIAGEN N.V.: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 166 QIAGEN N.V.: GEOGRAPHIC REVENUES, 2008 – 2010 ($MILLION)
TABLE 167 ROCHE: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 168 ROCHE: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 169 SANOFI-AVENTIS: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 170 SANOFI-AVENTIS: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 171 SANOFI-AVENTIS: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 172 SIEMENS: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 173 SIEMENS: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 174 SIEMENS: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 175 PROTEOME SCIENCES PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 176 PROTEOME SCIENCES PLC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 177 VERMILLION INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 178 VERMILLION INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

LIST OF FIGURES   

FIGURE 1 OVERVIEW OF BIOMARKERS MARKET
FIGURE 2 LIFE CYCLE OF A BIOMARKER
FIGURE 3 BIOMARKER MARKET
FIGURE 4 LEVEL OF IMPACT OF CHALLENGES
FIGURE 5 BIOMARKER DISCOVERY PROCESS
FIGURE 6 BIOMARKER DISCOVERY MARKET, 2011
FIGURE 7 OMICS TECHNOLOGIES & THE CENTRAL DOGMA
FIGURE 8 BIOMARKER DISCOVERY MARKET, BY OMICS TECHNOLOGIES, 2011
FIGURE 9 THE CENTRAL ROLE OF MASS SPECTROMETRY IN PROTEOMICS
FIGURE 10 BIOMARKER DISCOVERY USING 2-D DIGE & MS
FIGURE 11 TRANSCRIPTOMICS BIOMARKER DISCOVERY
FIGURE 12 BIOINFORMATICS MICROARRAY TOOLS
FIGURE 13 CLUSTER ANALYSIS OF OMICS DATA FOR BIOMARKER DISCOVERY
FIGURE 14 BIOMARKER SERVICES MARKET, BY SEGMENTS (%)
FIGURE 15 FLOW OF CLINICAL BIOMARKER SERVICES
FIGURE 16 DRUG DISCOVERY & DEVELOPMENT PROCESS
FIGURE 17 BIOMARKER DISCOVERY, BY INDICATIONS, 2011
FIGURE 18 KEY GROWTH STRATEGIES (JANUARY 2009 – DECEMBER 2011)

Filed in: Pharmaceutical
Tags: 
More Reports
Title Price Buy Now

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

“The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......
 $4950

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

“The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......
 $

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

“Digital Pharmacy market to register a CAGR of 17.0%  during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated  to grow at the highest rate during the forecast period” On the basis  ofdrug type, t......
 $4950

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......
 $4950

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases,  growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders,  rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on  product in 2021.” Based on products, the topical drug delivery the market is segmented into ......
 $4950

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

“Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......
 $4950

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......
 $4950

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

“Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......
 $4950

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

“Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......
 $4950

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027

The global Healthcare cloud computing market is projected to reach USD 89.4  billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......
 $4950
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy